Nootropics Index - Save on smarter supplements
Synthetic nootropics & research compounds

Centrophenoxine

Meclofenoxate (centrophenoxine), including hydrochloride forms

Centrophenoxine is another name for meclofenoxate, commonly supplied as the hydrochloride salt. Older trials in older adults found selective memory signals, but results were mixed and do not establish reliable cognitive enhancement in younger healthy users. Compare the exact salt, measured ingredient amount and evidence population, not a generic choline claim. Insomnia, activation and liver-enzyme changes are documented oral-product cautions; citicoline has an explicit co-use warning. WADA prohibits meclofenoxate in competition.

CholinergicSyntheticLimited Human EvidenceMixed EvidenceForm Dependent EvidencePopulation Specific EvidenceInsomnia Risk
Updated October 2026/9 min read/13 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
Extra caution

Who should avoid this or get expert review first

This is not a recommendation to use. These groups should treat the profile as a reason to slow down and verify safety, rules, and personal context.

  • Seizures, marked agitation, pregnancy or breastfeeding10The oral label flags seizure worsening and excessive excitability, and requires individualized pregnancy/lactation decisions. These circumstances need clinical assessment before use.
01

What is it?

Centrophenoxine and meclofenoxate

2

Centrophenoxine is a synonym for meclofenoxate, an ester related to DMAE rather than a dietary choline requirement. The free base has CAS 51-68-3; the hydrochloride salt has CAS 3685-84-5. The oral studies below generally concern the hydrochloride. Lucidril is a product name associated with that salt, not evidence that every powder or capsule has the same formulation.

What the older trials actually show

12

In a 1977 double-blind study of fit older adults, some measures of new-memory consolidation and reported alertness favored meclofenoxate. Other memory functions did not improve. This selective result is not proof of broad cognitive enhancement, nor direct evidence for a younger healthy person.

A cognitive null result matters

13

A 1986 double-blind crossover study enrolled 20 older residents with memory impairment; only nine completed it. No cognitive test showed a statistically significant advantage over placebo, despite a favorable trend on one learning task. Attrition and the small sample limit confidence in either direction.

The eight-week dementia study

7

A 1989 randomized trial enrolled 50 care-home residents with moderate dementia, averaging 77 years. Memory improvement was reported in 48% with centrophenoxine versus 28% with placebo. Four participants left because of intercurrent illness, and the analysis relied on semi-quantitative within-person comparisons. These old, small patient findings do not establish prevention or healthy-user enhancement.

Measured content is a separate question

4

A 2022 U.S. analysis detected centrophenoxine in all seven sampled products, at 79-251 mg per serving. Only one product declared a quantity within 10% of the measured amount. This was a label-accuracy study, not a benefit trial, and it does not establish the composition of every current batch.

02

Names, aliases and forms

Salt FormMeclofenoxate hydrochloride
Inn NameMeclofenoxate
Trade NameLucidril
Chemical NameDimethylaminoethyl p-chlorophenoxyacetate hydrochloride
Cas Numbers3685-84-5; 51-68-3
Molecular FormulaC12H17Cl2NO3
InchikeyFIVHOHCAXWQPGC-UHFFFAOYSA-N
03

Mechanisms of action

Metabolism is not a cognitive outcome

3

The human pharmacokinetic study measured chlorophenoxyacetic acid after meclofenoxate hydrolysis, not circulating parent drug. Metabolite exposure and formulation bioequivalence answer absorption questions; they do not demonstrate improved memory or concentration.

Brain-aging findings remain preclinical

9

In an aging-fish model, meclofenoxate partly offset reduced expression of neuronal-activity genes, but did not prevent the age-associated immune/inflammatory expression pattern. The authors did not regard the overall result as unambiguously positive. Such molecular work cannot validate human anti-aging or brain-cleaning claims.

Injury models are not ordinary enhancement

8

A rat study of chronic cerebral hypoperfusion reported better maze performance and less neuronal damage. An experimentally injured model is not a test of everyday focus in healthy humans, and its dose cannot be converted directly into a consumer regimen.

04

Potential effects and evidence map

Grade C: older, small and inconsistent human studies provide limited memory evidence in older populations. One healthy-older-adult study found selective effects; a dementia crossover trial found no significant cognitive benefit. Pharmacokinetic and animal studies do not establish enhancement, anti-aging benefit or long-term safety in healthy buyers.

Effect domainMagnitudeGrade
Memory / learning12
CumulativeConfidence: Low

Some older studies report selective memory improvements, but the findings are inconsistent and population-specific.

Note A null crossover study and limited methodological detail weaken any broad enhancement claim.

1/5
C
Focus / attention13
UnknownConfidence: Low

Reliable improvement in focus or attention for younger healthy users has not been established.

Note A small dementia trial found no statistically significant cognitive advantage.

0/5
E
Mental energy / wakefulness12
UnknownConfidence: Low

Self-reported alertness improved in one older-adult trial; this does not establish a wakefulness effect in younger users.

Note A subjective, population-specific signal, not proof of sustained stimulant benefit.

1/5
C
Cellular / long-term brain support9
UnknownConfidence: Low

Human anti-aging or long-term brain-protection benefits are unestablished.

Note The cited aging model had mixed molecular findings and was not a human trial.

0/5
E
05

Typical dosages and timing

Single research dose3200 mg

This was a single oral hydrochloride dose in 24 healthy men aged 22-30, comparing a capsule with a tablet after fasting and a one-week washout. No adverse events were reported. The trial did not test cognition, a daily routine or long-term safety; its dose is not a nootropic recommendation.

Historical research dose72000 mg/day

The eight-week dementia trial used this daily amount in divided tablet doses after a placebo run-in. It is a historical patient-study exposure, not a validated healthy-user dose and not a reason to escalate from a retail serving.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
PCPA plasma peak10Acute
2.1 hours
PCPA plasma half-life10Acute
8.4 hours
Older dementia trial7Cumulative
8 weeks
The timing cards measure different things10

PCPA means para-chlorophenoxyacetic acid, the measured metabolite. The peak and The time for blood levels to fall by half during the final elimination phase.Source cards come from six healthy adults receiving 300 mg once daily for 14 days in the manufacturer data. Neither number describes cognitive onset or how long a benefit lasts. The separate eight-week card is a patient-study window, not a cycle.

07

Safety, side effects and risk profile

Overstimulation / insomnia10
Confidence: Medium

The oral label lists insomnia and restlessness. Persistent sleep or activation symptoms warrant stopping and clinical review.

Note A documented oral-use signal, not inferred solely from a stimulant classification.

2/5
C
GI discomfort10
Confidence: Medium

Nausea, reduced appetite and stomach pain are listed oral-product effects.

Note Mild digestive symptoms alone do not explain the overall risk rating.

1/5
C
Headache / dizziness10
Confidence: Medium

Headache is a labeled effect. A small single-dose study observed none of the adverse events it monitored.

Note Absence in 24 men is not a long-term guarantee.

1/5
C
Liver / kidney caution10
Confidence: Medium

Liver-enzyme elevations are labeled. The historical table recorded AST/ALT increases in 15 of 10,470 cases.

Note This is a lab signal, not a stated liver-failure rate or a quantified healthy-user risk.

2/5
C
Interaction risk11
Confidence: High

AEMPS citicoline prescribing information says not to combine citicoline with meclofenoxate.

Note Applies to a specific combination; do not generalize it to every choline-related ingredient.

3/5
B
Legal / regulatory risk6
Confidence: High

WADA 2026 lists meclofenoxate as a specified stimulant prohibited in competition. A chemical identifier is not U.S. FDA approval.

Note Competition and jurisdictional rules are separate from ordinary-use toxicological risk.

4/5
B
Ordinary oral use10

For identified oral hydrochloride at clinical-dose ranges over weeks, low reflects documented sleep/activation effects and liver-test abnormalities that may require stopping or review. The liver-test signal makes minimal less appropriate; mild stomach symptoms alone would not. The checked ordinary-use evidence does not support moderate or high. This editorial judgment is not a measured healthy-user probability or proof of long-term safety.

Evidence limits10

The manufacturer monograph reports adverse reactions in 274 of 10,470 historical clinical cases (2.6%). These data are useful context, but lack the controls and population detail needed to predict risk in a healthy buyer or a modern retail product.

08

Interactions and cautions

Specific labeled warning11

The Spanish AEMPS prescribing information for oral citicoline explicitly says it should not be used together with meclofenoxate. A shared position in the choline/nootropic category is not a reason to combine them. This specific warning does not prove an identical interaction with every choline donor.

10

How it compares

Form comparison1

Free-base meclofenoxate and the hydrochloride are related, but their chemical mass and identifiers differ. Compare offers only after checking which form the amount describes. A Lucidril brand name, a loose powder and a capsule do not establish interchangeable formulation quality, and a DMAE product is a different comparison.

11

Practical buying and quality notes

  • At the October 12, 2026 check, this catalog had no active offers among 20 linked historical variants. That does not establish worldwide unavailability. The price search remains available; if listings return, verify form, package size, current availability and measured ingredient amount before comparing costs.
  • For like-for-like products, divide package cost by the total declared ingredient amount, then check whether a current batch assay supports that declaration. The seven-product study found substantial label disagreement, so a lower cost per labeled gram is not automatically a lower cost per measured gram or a better product.4
12

FAQ

What is the right centrophenoxine dose?

3

No daily dose is validated for healthy-user cognitive enhancement. The absorption-study dose and older patient regimen shown above answer different questions; combining them into a recommended range would be misleading.

How long does it last, and should it be cycled?

10

A metabolite half-life is not a cognitive-effect duration. The cited research does not establish an on/off cycle, tolerance-management schedule or safe long-term routine for healthy buyers.

Is centrophenoxine an ordinary choline supplement?

2

No. It is the synthetic meclofenoxate compound, commonly supplied as its hydrochloride salt. Do not transfer the evidence or dose of choline, citicoline or DMAE to it merely because they appear in similar nootropic discussions.

13

References

  1. U.S. FDA Substance Registration System. Meclofenoxate hydrochloride, UNII 5BK3070BDY. Accessed October 12, 2026.
  2. U.S. FDA Substance Registration System. Meclofenoxate, UNII C76QQ2I0RG. Accessed October 12, 2026.
  3. Zou JJ, Ji HJ, Wu DW, et al. Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers. Clinical Therapeutics. 2008;30(9):1651-1657.
  4. Cohen PA, Avula B, Khan I. The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements. Clinical Toxicology. 2022;60(10):1156-1158.
  5. Jedrejko K, Catlin O, Stewart T, et al. Unauthorized ingredients in nootropic dietary supplements: review and regulatory context. Drug Test Anal. 2023.
  6. World Anti-Doping Agency. 2026 Prohibited List, S6.B specified stimulants. Effective January 1, 2026.
  7. Pek G, Fulop T, Zs-Nagy I. Gerontopsychological studies using NAI on patients with organic psychosyndrome in a double-blind, comparative, randomized centrophenoxine trial. Archives of Gerontology and Geriatrics. 1989;9(1):17-30.
  8. Liao Y, Wang R, Tang XC. Centrophenoxine in a rat chronic cerebral ischemia cognition model. Acta Pharmacol Sin. 2004.
  9. Bakhtogarimov IR, Kudryavtseva AV, Krasnov GS, et al. Meclofenoxate and the aging-brain transcriptome in annual killifish. Int J Mol Sci. 2022.
  10. Kyowa Pharmaceutical Industry. Lucidril Tablets 100 mg interview form, seventh revision. July 2023. Manufacturer-authored document hosted by Packageinsert.jp.
  11. Spanish Agency of Medicines and Medical Devices (AEMPS). Citicolina Sandoz 1000 mg oral solution: Summary of Product Characteristics, section 4.5. Accessed October 12, 2026.
  12. Marcer D, Hopkins SM. The differential effects of meclofenoxate on memory loss in the elderly. Age and Ageing. 1977;6(2):123-131.
  13. Harris SJ, Dowson JH. The effects of meclofenoxate on cognitive performance in elderly individuals with memory impairment: a placebo-controlled study. International Journal of Geriatric Psychiatry. 1986;1(2):93-98.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.